“Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity.” Long F, Fong RH, Austin SK, Chen Z, Klose T, Fokine A, Liu Y, Porta J,
VLP Therapeutics, LLC. (“VLP”) announced that its Chief Executive Officer, Dr. Wataru Akahata, will present at the International Conference on Vaccines Research and Development 2015 on Tuesday, November 3, 2015, at 4:00 p.m. Eastern Time. The event will take place at the DoubleTree by Hilton Baltimore-BWI Airport in Linthicum, Maryland.
Co-Founder, Dr. Kuno was selected as 2015 America’s Richest Self-Made Women by Forbes.
VLP Therapeutics, LLC. (“VLP”) announced that it has initiated a research collaboration with the National Cancer Center’s National Cancer Center Research Institute in Japan. The collaboration will help facilitate VLP’s research and development of cancer vaccine candidates.
VLP Therapeutics to Initiate Collaboration with Johns Hopkins University Bloomberg School of Public Health
VLP Therapeutics, LLC. (“VLP”) announced that it has initiated a research collaboration with John’s Hopkins University Bloomberg School of Public Health to research VLP’s malaria vaccine candidates.
VLP Therapeutics was featured in CEOCFO (April 27, 2015).